Sep 18, 2024, 12:30
Mark Lewis: RAS(ON) inhibitor responses in pancreatic adenocarcinoma
Mark Lewis posted the following on X:
“Per Ignacio Garrido-Laguna, RMC-6236, a RAS(ON) multiselective inhibitor, can induce responses across a variety of KRAS mutations even in heavily pretreated patients with pancreatic adenocarcinoma!”
Source: Mark Lewis/X
Mark A. Lewis is the Director of Gastrointestinal Oncology at Intermountain Healthcare in Utah, the Co-Chair of adolescent and young adult (AYA) oncology in the SWOG cooperative group, and the Vice President of American Multiple Endocrine Neoplasia Support. Dr. Lewis is also a well-known patient advocate and social media influencer. His interests are neuroendocrine tumors and cancer syndromes.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 11:52
Dec 21, 2024, 11:30
Dec 21, 2024, 11:25
Dec 21, 2024, 11:18
Dec 21, 2024, 11:12
Dec 21, 2024, 11:06